Varencline among five drugs accepted by SMC
The smoking cessation medicine varencline is among five drugs accepted by the Scottish
Medicines Consortium for use in NHS Scotland this month.
Varencline (Champix) has been accepted for smoking cessation treatment
for adults. In addition: busulfan (Busilvex) has been accepted as a conditioning
treatment before conventional haematopoietic progenitor cell transplantation;
clofarabine (Evoltra) has been accepted for the treatment of acute lymphoblastic
leukaemia in patients under 21 years of age; and ertapenem (Invanz) has
been accepted for the treatment of diabetic foot infections of the skin
and soft tissue.
Daptomycin has been accepted, following an abbreviated submission, for
the treatment of complicated skin and soft tissue infections in adults
who have known or suspected methicillin-resistant Staphylococcus
aureus infection. However, Omalizumab (Xolair) was not accepted as an add-on
asthma therapy in adult and adolescent patients with severe persistent
asthma. The SMC concluded that the
economic case for its use had not been demonstrated. |
The
Pharmaceutical Journal
Acrobat
Reader